N/A
Completed N=82
TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Source: ClinicalTrials.gov NCT03306199 ↗Enrolled (actual)
82
Serious AEs
23.9%
Results posted
Apr 2019
Primary outcomePrimary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants
Summary
A retrospective study to evaluate Turbo Power laser atherectomy + drug coated balloon (DCB) angioplasty for the treatment of femoropopliteal de novo/restenotic lesions and in-stent restenosis (ISR).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Free From Target Lesion Revascularization (TLR) |
52 | — |
Eligibility Criteria
Inclusion Criteria
- All patients treated for femoropopliteal de novo/restenotic lesions or in-stent restenosis using Turbo Power laser atherectomy plus drug coated balloon angioplasty
Exclusion Criteria
- Any incomplete data on procedural approach and treatment
Data sourced from ClinicalTrials.gov (NCT03306199). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.